Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jul;53(7):2204-2210.
doi: 10.1161/STROKEAHA.121.037298. Epub 2022 Mar 21.

Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial

Lydia Foster  1 , Laura Robinson  2 , Sharon D Yeatts  1 , Robin A Conwit  3 , Amjad Shehadah  2 , Vasileios Lioutas  2 , Magdy Selim  2 ; i-DEF Investigators
Affiliations
Clinical Trial

Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial

Lydia Foster et al. Stroke. 2022 Jul.

Abstract

Background: There are limited data on the trajectory of recovery and long-term functional outcomes after intracerebral hemorrhage (ICH). Most ICH trials have conventionally assessed outcomes at 3 months following the footsteps of ischemic stroke. The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period. We evaluated the trajectory of mRS among trial participants and examined the effect of deferoxamine on this trajectory.

Methods: We performed a post hoc analysis of the i-DEF trial, a multicenter, randomized, placebo-controlled, double-blind, futility-design, phase 2 clinical trial, based on the actual treatment received. Favorable outcome was defined as mRS score of 0-2. A generalized linear mixed model was used to evaluate the outcome trajectory over time, as well as whether the trajectory was altered by deferoxamine, after adjustments for randomization variables, presence of intraventricular hemorrhage, and ICH location.

Results: A total of 291 subjects were included in analysis (145 placebo and 146 deferoxamine). The proportion of patients with mRS score of 0-2 continually increased from day 7 to 180 in both groups (interaction P<0.0001 for time in main effects model), but treatment with deferoxamine favorably altered the trajectory (interaction P=0.0010). Between day 90 and 180, the deferoxamine group improved (P=0.0001), whereas there was not significant improvement in the placebo arm (P=0.3005).

Conclusions: A large proportion of patients continue to improve up to 6 months after ICH. Future ICH trials should assess outcomes past 90 days for a minimum of 6 months. In i-DEF, treatment with deferoxamine seemed to accelerate and alter the trajectory of recovery as assessed by mRS.

Registration: URL: https://www.

Clinicaltrials: gov; Unique identifier: NCT02175225.

Keywords: clinical trial; deferoxamine; hemorrhage; ischemic stroke; recovery.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Favorable Outcome (mRS 0-2) Over Time by Treatment Received
Figure 2:
Figure 2:
Distribution of mRS Scores Over Time
See this image and copyright information in PMC

References

    1. Krishnamurthi RV, Moran AE, Forouzanfar MH, Bennett DA, Mensah GA, Lawes CM, Barker-Collo S, Conor M, Roth GA, Sacco R, et al.; Global Burden of Diseases, Injuries, and Risk Factors 2010 Study Stroke Expert Group. The global burden of hemorrhagic stroke: a summary of findings from the GBD 2010 study. Glob Heart. 2014; 9:101–106. - PubMed
    1. Lee KB, Lim SH, Kim KH, Kim KJ, Kim YR, Chang WN, Yeom JW, Kim YD, Hwang BY. Six-month functional recovery of stroke patients: a multi-time-point study. Int. J. Rehab. Res 2015;38:173–180. - PMC - PubMed
    1. Lee KB, Kim JS, Hong BY, Kim YD, Hwang BY, Lim SH. The motor recovery related with brain lesions in patients with intracranial haemorrhage. Behav Neurol. 2015; 2015: 258161. - PMC - PubMed
    1. Saulle M, Schambra H. Recovery and rehabilitation after intracerebral hemorrhage. Semin Neurol. 2016;36:306–312. - PMC - PubMed
    1. Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM. et al. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): A multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019;18:428–438. - PMC - PubMed

Publication types

Associated data

LinkOut - more resources